These correlations provide both mechanistic insight and potential biomarker utility, highlighting that modulation of the SIRT1/Nrf2/NLRP3 axis could represent a promising therapeutic approach to alleviate both molecular dysfunction and clinical burden in PD. The gene discussed is NLRP3; the disease is Parkinson disease.